Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
2,114 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations | terminated | Phase 2 | 19 | PfizerINDUSTRY | 6 | Jan 8, 2019 | clinicaltrials |
| NCT02633800 | Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) | terminated | Phase 2 | 87 | Daiichi SankyoINDUSTRY | 7 | Jan 7, 2019 | clinicaltrials |
| NCT01685190 |
| A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer(PIVOTAL) |
| unknown |
| Phase 2 |
| 124 |
| Institute of Cancer Research, United KingdomOTHER |
| 1 |
| Jan 4, 2019 |
| clinicaltrials |
| NCT02391116 | Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 67 | BayerINDUSTRY | 10 | Jan 4, 2019 | clinicaltrials |
| NCT01722292 | A Study of LY2940680 in Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 26 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01668459 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel(CabB1) | completed | Phase 2 / Phase 3 | 20 | Dr Anjali ZarkarOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02044822 | Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion | terminated | Phase 2 | 102 | Gilead SciencesINDUSTRY | 14 | Nov 19, 2018 | clinicaltrials |
| NCT03292757 | FLOTOR Pilot Study(FLOTOR) | completed | Phase 1 / Phase 2 | 21 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00782067 | Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 116 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 15, 2018 | clinicaltrials |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer(MATRIX EG) | completed | Phase 2 | 72 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Nov 2, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00641095 | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma(MCLPIII) | completed | Phase 2 / Phase 3 | 370 | University College, LondonOTHER | 2 | Oct 31, 2018 | clinicaltrials |
| NCT00963105 | Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 104 | CelgeneINDUSTRY | 8 | Oct 31, 2018 | clinicaltrials |
| NCT01817257 | Anticoagulation Length in Cancer Associated Thrombosis(ALICAT) | terminated | Phase 2 | 2 | Cardiff UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01972451 | Feasibility of Reduction in Right Sided Bowel Cancer Through Contrast Enhanced Colonoscopy(CONSCOP) | completed | Phase 2 | 1,320 | Lisette NixonOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01032057 | Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery(SCALOP) | completed | Phase 2 | 114 | Lisette NixonOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation(SCOPE2) | unknown | Phase 2 / Phase 3 | 584 | Lisette NixonOTHER_GOV | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00513656 | A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain | completed | Phase 2 | 230 | Mundipharma Research GmbH & Co KGINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT02594163 | Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 25 | Seagen Inc.INDUSTRY | 7 | Oct 16, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer(NGR018) | completed | Phase 2 | 119 | AGC Biologics S.p.A.INDUSTRY | 2 | Sep 27, 2018 | clinicaltrials |
| NCT01111825 | Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 99 | Puma Biotechnology, Inc.INDUSTRY | 6 | Sep 26, 2018 | clinicaltrials |
| NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer(CARRIE) | completed | Phase 2 | 88 | Merrimack PharmaceuticalsINDUSTRY | 6 | Sep 18, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT01334060 | WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation(WIN) | completed | Phase 2 | 23 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | completed | Phase 2 | 69 | AGC Biologics S.p.A.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | completed | Phase 2 | 233 | Puma Biotechnology, Inc.INDUSTRY | 31 | Aug 9, 2018 | clinicaltrials |
| NCT02525068 | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC(RE-AKT) | unknown | Phase 2 | 136 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01795976 | NY-ESO-1 T Cells in OG Cancer(ATTACK-OG) | terminated | Phase 2 | 2 | Fiona ThistlethwaiteOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01852292 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | terminated | Phase 2 | 157 | Novartis PharmaceuticalsINDUSTRY | 18 | Jul 24, 2018 | clinicaltrials |
| NCT02540928 | AMG 319 in HPV Positive and Negative HNSCC | terminated | Phase 2 | 35 | Cancer Research UKOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00458913 | Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 82 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01208064 | Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy | terminated | Phase 2 / Phase 3 | 102 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 12, 2018 | clinicaltrials |
| NCT00074087 | Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides | completed | Phase 2 | 49 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 9, 2018 | clinicaltrials |
| NCT00802945 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer | completed | Phase 2 | 70 | Nektar TherapeuticsINDUSTRY | 3 | Jul 9, 2018 | clinicaltrials |
| NCT01019434 | Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 111 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 9, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT01134497 | Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer(PLANET) | withdrawn | Phase 2 | 0 | Cardiff UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT02273973 | A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | completed | Phase 2 | 334 | Genentech, Inc.INDUSTRY | 22 | May 21, 2018 | clinicaltrials |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 13 | Philogen S.p.A.INDUSTRY | 6 | May 18, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials